Lenacapavir: A Twice-Yearly HIV Prevention Injection Approved by the FDA – Promise and Challenges
Lenacapavir: A Twice-Yearly HIV Prevention Injection Approved by the FDA – Promise and Challenges The Food and Drug Administration (FDA) has approved Gilead Sciences’ lenacapavir as a twice-yearly pre-exposure prophylaxis (PrEP) injection, marking a significant advancement in HIV prevention. This approval follows successful Phase III clinical trials demonstrating a remarkably high efficacy rate, exceeding that of daily PrEP regimens. The drug, marketed under the brand name Yeztugo, achieved a 100% prevention rate in cisgender women and a 99.9% prevention rate…